Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 1, 2017, Pages 31-38

  Motamed, Nima ^a   Rabiee, Behnam ^b   Poustchi, Hossein ^c   Dehestani, Babak ^d   Hemasi, Gholam Reza ^b   Khonsari, Mahmood Reza ^b   Maadi, Mansooreh ^b   Saeedian, Fatemeh Sima ^b   Zamani, Farhad ^b  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

10 years cardiovascular risk; Epidemiology; Non alcoholic fatty liver disease

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC HEPATITIS; COHORT ANALYSIS; COMPARATIVE STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; ADOLESCENT; BLOOD; BODY MASS; CHILD; COMPLICATION; DIABETIC COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 85013150614     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.07.005     Document Type: Article

References (34)

1. [1] Angulo, P., Lindor, K.D., Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17:Suppl. (2002), S186–S190.
2. [2] Ahmed, M., Non-alcoholic fatty liver disease in 2015. World J Hepatol 7 (2015), 1450–1459.
3. [3] Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 178 (2013), 38–45.
4. [4] Wong, V.W., Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 28 (2013), 18–23.
5. [5] Amirkalali, B., Poustchi, H., Keyvani, H., Khansari, M.R., Ajdarkosh, H., Maadi, M., et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health 43 (2014), 1275–1283.
6. [6] Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
7. [7] Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
8. [8] Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 33 (2012), 1190–1200.
9. [9] Maurantonio, M., Ballestri, S., Odoardi, M.R., Lonardo, A., Loria, P., Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch Med Res 42 (2011), 337–353.
10. [10] Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
11. [11] Otgonsuren, M., Stepanova, M., Gerber, L., Younossi, Z.M., Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci 58 (2013), 1132–1140.
12. [12] Younossi, Z.M., Otgonsuren, M., Venkatesan, C., Mishra, A., In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 62 (2013), 352–360.
13. [13] D'Agostino, R.B. Sr., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 (2008), 743–753.
14. [14] Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001), 2486–2497.
15. [15] Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B. Sr., Gibbons, R., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
16. [16] Zamani, F., Sohrabi, M., Alipour, A., Motamed, N., Saeedian, F.S., Pirzad, R., et al. Prevalence and risk factors of cholelithiasis in Amol city, northern Iran: a population-based study. Arch Iran Med 17 (2014), 750–754.
17. [17] Dogan, S., Celikbilek, M., Yilmaz, Y.K., Sarikaya, S., Zararsiz, G., Serin, H.I., et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 27 (2015), 298–304.
18. [18] Treeprasertsuk, S., Leverage, S., Adams, L.A., Lindor, K.D., St Sauver, J., Angulo, P., The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 32 (2012), 945–950.
19. [19] Pacifico, L., Anania, C., Martino, F., Cantisani, V., Pascone, R., Marcantonio, A., et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 52 (2010), 1643–1651.
20. [20] Salvi, P., Ruffini, R., Agnoletti, D., Magnani, E., Pagliarani, G., Comandini, G., et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 28 (2010), 1699–1707.
21. [21] Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005), 473–480.
22. [22] Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
23. [23] Oni, E.T., Agatston, A.S., Blaha, M.J., Fialkow, J., Cury, R., Sposito, A., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230 (2013), 258–267.
24. [24] Xu, X., Lu, L., Dong, Q., Li, X., Zhang, N., Xin, Y., et al. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis, 14, 2015, 158.
25. [25] Kucukazman, M., Ata, N., Yavuz, B., Dal, K., Sen, O., Deveci, O.S., et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 25 (2013), 147–151.
26. [26] Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47 (2015), 181–190.
27. [27] Eslami, L., Merat, S., Malekzadeh, R., Nasseri-Moghaddam, S., Aramin, H., Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev, 12, 2013, CD008623.
28. [28] Pastori, D., Polimeni, L., Baratta, F., Pani, A., Del Ben, M., Angelico, F., The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47 (2015), 4–11.
29. [29] Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376 (2010), 1916–1922.
30. [30] Nelson, A., Torres, D.M., Morgan, A.E., Fincke, C., Harrison, S.A., A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43 (2009), 990–994.
31. [31] Otgonsuren, M., Estep, M.J., Hossain, N., Younossi, E., Frost, S., Henry, L., et al. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 29 (2014), 2006–2013.
32. [32] Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
33. [33] Rockey, D.C., Caldwell, S.H., Goodman, Z.D., Nelson, R.C., Smith, A.D., American Association for the Study of Liver D. Liver biopsy. Hepatology 49 (2009), 1017–1044.
34. [34] Wieckowska, A., Feldstein, A.E., Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 28 (2008), 386–395.